Digital Breast Tomosynthesis Market - Global Forecast 2025-2030

The Digital Breast Tomosynthesis Market size was estimated at USD 4.41 billion in 2024 and expected to reach USD 5.09 billion in 2025, at a CAGR 14.90% to reach USD 10.15 billion by 2030.

Digital breast tomosynthesis has emerged as a pivotal advancement in breast cancer detection, transforming the diagnostic landscape with its three-dimensional imaging capabilities. Unlike conventional two-dimensional mammography, tomosynthesis captures multiple projections of breast tissue at varying angles and reconstructs them into a pseudo-3D representation. This reduction of tissue overlap directly enhances lesion conspicuity, leading to earlier and more accurate identification of malignancies. As a result, recall rates have fallen and invasive cancer detection has risen, validating the clinical value of this technology.

The clinical evidence supporting tomosynthesis has grown substantially, with long-term studies demonstrating its superiority over traditional mammography. A decade-long analysis published in Radiology showed that tomosynthesis improved cancer detection rates and led to significant reductions in advanced-stage diagnoses, underscoring its role in improving patient outcomes. Concurrently, the Tomosynthesis Mammographic Imaging Screening Trial (TMIST) reached its enrollment target of over 108,000 women, positioning itself to deliver definitive, randomized controlled data that will shape personalized screening guidelines when results emerge in 2027.

In April 2025, the U.S. government implemented a universal 10% tariff on imported goods, including high-value medical imaging equipment, with higher levies on products from specific trading partners such as China. This policy shift has introduced cost pressures on radiology vendors whose supply chains span multiple regions. The specter of an EU-focused tariff of up to 50% further exacerbates concerns, particularly among U.S. hospitals reliant on state-of-the-art European technology.

Analyzing the market by component reveals that hardware systems remain foundational, yet service and software offerings are rapidly gaining traction through AI-driven interpretation platforms and cloud-based analytics that enhance radiologist workflow efficiencies. End users exhibit differentiated demand: academic and research institutes spearhead pilot implementations for novel technologies, while breast cancer clinics prioritize specialized tomosynthesis modules. Diagnostic imaging centers balance throughput and patient experience by investing in both integrated tomosynthesis suites and standalone systems, with hospitals leveraging high-capacity installations to support multidisciplinary care teams. From an application standpoint, screening programs benefit from volumetric imaging’s ability to detect subtle lesions early, whereas diagnostic uses leverage the modality’s high resolution for problem-solving exams. Technologically, integrated tomosynthesis units within full-field mammography platforms coexist with standalone devices optimized for space-constrained environments. Installation trends showcase fixed units in established clinical settings alongside mobile units deployed in community outreach initiatives to bridge access gaps.

In North America, widespread adoption has been catalyzed by supportive reimbursement policies and strong consumer demand, with over 90% of breast imaging centers now equipped with tomosynthesis systems. Europe’s landscape is shaped by evolving guidelines from the European Society of Breast Imaging, which endorse tomosynthesis as an alternative to mammography in high-volume centers and integrate risk-stratified screening recommendations. Within the Middle East and Africa, investment is concentrated in urban healthcare hubs, where recent procurement of advanced imaging is part of broader initiatives to enhance oncology services. The Asia-Pacific region is experiencing rapid growth driven by government-led screening programs in China, Japan and India, alongside strategic partnerships that facilitate technology transfer and local manufacturing to meet expanding demand.

Leading innovators are shaping the evolution of tomosynthesis ecosystems. GE Healthcare’s MyBreastAI suite exemplifies the integration of deep-learning algorithms with volumetric imaging, enhancing diagnostic accuracy while streamlining radiologist workflows. iCAD’s ProFound Detection Version 4.0 leverages convolutional neural networks to boost cancer detection rates in dense breasts by 50%, validated through recent FDA clearance. Siemens Healthineers continues investing in localized production to mitigate trade risks, coupling its Varian heritage with advanced detector technologies that improve image resolution and dose efficiency. Hologic remains at the forefront of hardware innovation, advancing tomosynthesis holder ergonomics and synthetic 2D imaging to reduce patient dose while maintaining diagnostic performance.

Industry leaders must embrace strategic diversification to navigate geopolitical uncertainties. Establishing regional manufacturing footprints or obtaining origin-based tariff exemptions can safeguard supply chains and preserve margins, as evidenced by successful localization initiatives among major vendors. Integrating AI-powered software into service contracts can unlock new revenue models while improving turnaround times and diagnostic consistency. Emphasizing mobile unit deployments alongside traditional sites will expand screening outreach and address disparities in access. Moreover, proactively engaging with policymakers and advocacy groups to advocate for medical device tariff exemptions will be critical to preserving innovation incentives and ensuring patient access to advanced imaging.

This analysis is grounded in a rigorous, multistage methodology. Initially, secondary research was conducted by reviewing peer-reviewed journals, regulatory filings and industry white papers to capture the latest evidence and policy developments. Complementing this, expert interviews with radiology directors, clinical researchers and supply chain specialists provided firsthand perspectives on operational challenges and adoption drivers. Data validation employed cross-referencing among multiple sources, ensuring consistency in technology performance metrics and regulatory timelines. Finally, insights were synthesized through iterative thematic analysis to distill actionable intelligence that aligns with stakeholder priorities.

The confluence of clinical validation, technological innovation and shifting policy frameworks has positioned digital breast tomosynthesis as a cornerstone of modern breast imaging. Robust evidence from longitudinal studies and landmark trials confirms its diagnostic superiority, while AI accelerates interpretation and personalizes screening pathways. Although tariff pressures present a near-term headwind, proactive supply chain resilience strategies and ongoing advocacy can mitigate these disruptions. Ultimately, stakeholders who align investments with emerging clinical guidelines, optimize service and software integration, and champion equitable access will lead the charge toward improved breast cancer detection and patient care.

Elevate your strategic planning and operational efficiencies by securing exclusive access to the complete analysis of digital breast tomosynthesis market trends. Connect directly with Ketan Rohom, Associate Director, Sales & Marketing, to tailor a solution package that meets your organization’s unique needs and unlocks the insights that will drive competitive advantage and sustainable growth. Reach out today to ensure your team is equipped with the comprehensive intelligence required to navigate this dynamic market landscape and capitalize on emerging opportunities.